- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-Drug Conjugates: The New Frontier of Chemotherapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 15, Pages 5510
Publisher
MDPI AG
Online
2020-08-03
DOI
10.3390/ijms21155510
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
- (2020) A.C. Marques et al. JOURNAL OF CONTROLLED RELEASE
- Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
- (2020) Laurence Gauzy-Lazo et al. SLAS Discovery
- Gold Nanoparticles- Boon in Cancer Theranostics
- (2020) Mehak Jindal et al. CURRENT PHARMACEUTICAL DESIGN
- Crosslinked polymer nanocapsules for therapeutic, diagnostic, and theranostic applications
- (2020) Haotian Sun et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Liposomes for enhanced cellular uptake of anticancer agents
- (2020) Gamal M. El Maghraby et al. Current Drug Delivery
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
- (2019) Gabriel Rinnerthaler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Polatuzumab Vedotin: First Global Approval
- (2019) Emma D. Deeks DRUGS
- Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
- (2019) Sajad Yaghoubi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Considerations for the Design of Antibody-Based Therapeutics
- (2019) Dennis R. Goulet et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
- (2019) Nicholas C. Yoder et al. MOLECULAR PHARMACEUTICS
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice
- (2019) Hao Wang et al. TALANTA
- EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
- (2018) Emily Capone et al. JOURNAL OF CONTROLLED RELEASE
- Improving theIn VivoEfficacy of an Anti-Tac (CD25) Immunotoxin byPseudomonasExotoxin A Domain II Engineering
- (2018) Gilad Kaplan et al. MOLECULAR CANCER THERAPEUTICS
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins
- (2018) Francesco Giansanti et al. Toxins
- Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy
- (2018) Naidu S. Chowdari et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Moxetumomab Pasudotox: First Global Approval
- (2018) Sohita Dhillon DRUGS
- Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates
- (2018) Francesco Giansanti et al. JOURNAL OF CONTROLLED RELEASE
- Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates
- (2017) Sergii Kolodych et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin
- (2017) Anne-Chloé Dhez et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo
- (2017) Alberto Dal Corso et al. JOURNAL OF CONTROLLED RELEASE
- Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
- (2017) Hao Chen et al. MOLECULES
- Enzymatic conjugation using branched linkers for constructing homogeneous antibody–drug conjugates with high potency
- (2017) Yasuaki Anami et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates
- (2017) Thomas H. Pillow et al. Chemical Science
- Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
- (2017) Muhammad Kalim et al. Drug Design Development and Therapy
- EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
- (2017) Emily Capone et al. Oncotarget
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- (2017) Ricarda M. Hoffmann et al. OncoImmunology
- Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity
- (2016) Edward J. Hennessy BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera
- (2016) Alfredo Errico Provenzano et al. Microbial Cell Factories
- Antibody-drug conjugates: Current status and future perspectives
- (2016) Rémy Gébleux et al. PHARMACOLOGY & THERAPEUTICS
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
- (2016) Gilad Kaplan et al. Toxins
- Precision cancer medicine: where to target?
- (2015) Qiang Yu et al. ACTA PHARMACOLOGICA SINICA
- Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
- (2015) Magdalena Dorywalska et al. BIOCONJUGATE CHEMISTRY
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- (2015) Eunhee G. Kim et al. Biomolecules & Therapeutics
- Current methods for the synthesis of homogeneous antibody–drug conjugates
- (2015) Alicja M. Sochaj et al. BIOTECHNOLOGY ADVANCES
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- PDZ Domain in the Engineering and Production of a Saporin Chimeric Toxin as a Tool for targeting Cancer Cells
- (2015) Francesco Giansanti et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
- (2015) R. Gebleux et al. MOLECULAR CANCER THERAPEUTICS
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability
- (2015) Satish K. Singh et al. PHARMACEUTICAL RESEARCH
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)
- (2015) Pramudita R. Prasetyanti et al. Oncotarget
- Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy
- (2015) Magdalena Dorywalska et al. PLoS One
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Human Antibody Production in Transgenic Animals
- (2014) Marianne Brüggemann et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System
- (2014) Erik S. Zimmerman et al. BIOCONJUGATE CHEMISTRY
- β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update
- (2014) Isabelle Tranoy-Opalinski et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
- (2014) W. Dokter et al. MOLECULAR CANCER THERAPEUTICS
- A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
- (2014) A. E. Prota et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A general approach to site-specific antibody drug conjugates
- (2014) Feng Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo
- (2014) Gianluca Sala et al. Translational Oncology
- Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
- (2014) R Ghasemi et al. Oncogenesis
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers
- (2013) S. V. Govindan et al. MOLECULAR CANCER THERAPEUTICS
- Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin
- (2012) Tetsuya Tanimoto et al. INVESTIGATIONAL NEW DRUGS
- Disulfide bond structures of IgG molecules
- (2012) Hongcheng Liu et al. mAbs
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
- (2012) J. Y. Axup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
- (2011) Lutz F. Tietze et al. CURRENT PHARMACEUTICAL DESIGN
- Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines
- (2011) A. Cimini et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Shaping development with ESCRTs
- (2011) Tor Erik Rusten et al. NATURE CELL BIOLOGY
- Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)
- (2010) Dyeison Antonow et al. CHEMICAL REVIEWS
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
- Engineering a switchable toxin: the potential use of PDZ domains in the expression, targeting and activation of modified saporin variants
- (2009) F. Giansanti et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
- (2008) E. Oflazoglu et al. CLINICAL CANCER RESEARCH
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started